DxTerity today announced that three abstracts featuring the company’s RNA-based immune monitoring technology have been accepted for presentation at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, taking place November 6–11, 2026 at the Orange County Convention Center in Orlando, Florida.

The three abstracts apply RNA gene signature measurement to systemic lupus erythematosus (SLE), a disease in which clinical presentation and treatment response vary widely between patients. Together they examine whether molecular signatures of immune activity can help identify which patients are likely to have severe disease, which are responding inadequately to standard of care, and which show signs of resistance to targeted interferon-blocking therapy.

Accepted Abstracts

1. The Type I Interferon (IFN-1) Gene Signature Identifies Systemic Lupus Erythematosus Patients More Likely to Have Severe Disease Including Activity in Immunologic, Renal and Hematologic Domains

Demonstrated in a cohort of 943 samples from 395 SLE patients that IFN-1 High patients were more 3 times more likely to have Immunologic (Positive for dsDNA and Low Complement) symptoms, and 2 times more likely to have renal symptoms and active lupus nephritis than IFN-1 low patients (p<0.0001).

2. Low Density Granulocyte Neutrophil Signature Identifies Systemic Lupus Erythematosus

Patients with Inadequate Response to Standard of Care Treatment

Demonstrated in a cohort of 395 SLE patients, at time of initial enrollment in the study, patients that were LDG-Neutrophil high were 4 times more likely to have active lupus nephritis and 28 times less likely to be in the Prevalent cohort with well managed disease (p<0.0001).

3. Monitoring the Biological Response to Anifrolumab in Real World Setting Using Interferon Gene Signature Shows Signs of Therapy Resistance in Select SLE Patients

Uses serial Type I Interferon gene signature measurements (IFN-1 testing) in a cohort of 17 patients being treated with the interferon receptor blocking drug anifrolumab, 2 patients showed loss of drug efficacy based on increasing IFN-1 score and return to IFN-1 high, while 1 patient is showing initialsigns of therapy resistance due to increasing IFN-1 score. Both IFN-1 high patients experienced disease flares.

Presentation Details

Meeting: ACR Convergence 2026, American College of Rheumatology

Venue: Orange County Convention Center, Orlando, Florida

Session: Poster Session C

Date: Tuesday, November 10, 2026

Time: 10:30 a.m. – 12:30 p.m. ET

“Exciting to see the growth in evidence on the utility of modular assessment of immune health leveraging

our Modular Immune Profile Assay. Grateful for the contributions and guidance of all our collaborators at

Lupus Research Alliance.”

said Bob Terbrueggen, CEO of DxTerity.

Full abstract text will be available through the ACR Convergence online program. DxTerity representatives will be available at the meeting to discuss the data and the company’s immune monitoring programs.

About DxTerity

DxTerity’s patient-focused mission is to bring the power of at-home RNA-based genomic monitoring to improve the management of immune-mediated diseases and overall patient well-being. DxTerity’s Type 1 Interferon (IFN-1) and Modular Immune Profile tests are run in the company’s CAP-accredited, CLIA-certified laboratory in Torrance, California. DxTerity also holds ISO 13485 certification for its product

development services.